共 406 条
[1]
Bray F(2018)Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 68 394-424
[2]
Ferlay J(1995)Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up N Engl J Med 332 901-906
[3]
Soerjomataram I(2018)Abstract GS1-01: increasing the dose density of adjuvant chemotherapy by shortening intervals between courses or by sequential drug administration significantly reduces both disease recurrence and breast cancer mortality: an EBCTCG meta-analysis of 21,000 women in 16 randomised trials Cancer Res 78 GS1-G01
[4]
Siegel RL(2017)Impact of chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) on cancer treatment outcomes: an overview about well-established and recently emerging clinical data Crit Rev Oncol Hematol 120 163-179
[5]
Torre LA(2016)Incidence and predictors of febrile neutropenia among early-stage breast cancer patients receiving anthracycline-based chemotherapy in Korea Oncology 91 274-282
[6]
Jemal A(2007)Hematopoietic growth factors in the treatment of acquired bone marrow failure states Semin Hematol 44 138-147
[7]
Bonadonna G(1996)Filgrastim (r-metHuG-CSF): the first 10 years BLOOD 88 1907-1929
[8]
Valagussa P(2011)2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours Eur J Cancer 47 8-32
[9]
Moliterni A(2018)Primary febrile neutropenia prophylaxis for patients who receive FEC-D chemotherapy for breast cancer: a systematic review J Glob Oncol 4 1-8
[10]
Zambetti M(2011)Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study Curr Med Res Opin 27 79-86